MedDataX Logo

Histamines and Central Hemodynamics

NCT ID: NCT07285031

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-31

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

When we exercise, more blood flow goes to our muscles, challenging our blood vessels. Following exercise, blood flow remains elevated and seems to be the reason for many of the positive cardiovascular benefits that occur with exercise. When the actions of histamine, a molecule primarily known for its role in allergies, are blocked, there is an attenuated blood flow response following exercise. However, this effect has never been studied in the blood vessels that supply our lungs. The purpose of this study is to examine the effects of histamines on pulmonary hemodynamics following exercise.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Histamine Exercise

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

histamine exercise pulmonary blood flow pulmonary function femoral blood flow

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blockade + Exercise Bout

Participants will ingest histamine H1 receptor blockade before performing an exercise bout.

Group Type EXPERIMENTAL

Diphenhydramine hydrochloride

Intervention Type DRUG

H1 receptor antagonist: 50mg Diphenhydramine Hydrochloride

Exercise Bout

Intervention Type OTHER

Participants will complete a total of three 5-minute high intensity exercise intervals, interspersed with 5-minute lower intensity exercise bouts (4 total), for a total of 35 minutes.

Placebo + Exercise Bout

Participants will ingest a placebo before an exercise bout.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Placebo

Exercise Bout

Intervention Type OTHER

Participants will complete a total of three 5-minute high intensity exercise intervals, interspersed with 5-minute lower intensity exercise bouts (4 total), for a total of 35 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diphenhydramine hydrochloride

H1 receptor antagonist: 50mg Diphenhydramine Hydrochloride

Intervention Type DRUG

Placebo

Placebo

Intervention Type OTHER

Exercise Bout

Participants will complete a total of three 5-minute high intensity exercise intervals, interspersed with 5-minute lower intensity exercise bouts (4 total), for a total of 35 minutes.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age: 19 - 39.
2. Willing to visit the lab on 3 separate occasions.

Exclusion Criteria

1. Previously diagnosed heart condition,
2. Previously diagnosed lung condition (including asthma),
3. Previously diagnosed metabolic condition,
4. Currently smokers (cigarettes, electronic cigarettes, cannabis) or who have smoked within the last 3 months,
5. Resting blood pressure \>140/90 mmHg,
6. Unable to obtain appropriate quality ultrasound images of the heart.,
7. Individuals without tricuspid regurgitation at rest to allow assessment of the primary outcome,
8. Pregnant or trying to become pregnant,
9. Breastfeeding,
10. Chronically take antihistamines (i.e. daily),
11. History of adverse reactions to antihistamines,
12. Never taken antihistamines previously,
13. Currently taking any medications (including oral contraceptives).
Minimum Eligible Age

19 Years

Maximum Eligible Age

39 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of British Columbia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Neil Eves

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of British Columbia

Kelowna, British Columbia, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Neil Eves, PhD

Role: CONTACT

Phone: (250) 807-9676

Email: [email protected]

Cassidy Williams, BHK

Role: CONTACT

Phone: (250) 807-9676

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Neil Eves, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H25-01909

Identifier Type: -

Identifier Source: org_study_id